Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aytu Biopharma (AYTU) Consolidated Net Income (2016 - 2025)

Historic Consolidated Net Income for Aytu Biopharma (AYTU) over the last 17 years, with Q2 2025 value amounting to $62000.0.

  • Aytu Biopharma's Consolidated Net Income rose 10500.4% to $62000.0 in Q2 2025 from the same period last year, while for Dec 2025 it was $116000.0, marking a year-over-year increase of 10869.57%. This contributed to the annual value of $620000.0 for FY2025, which is 11865.22% up from last year.
  • Per Aytu Biopharma's latest filing, its Consolidated Net Income stood at $62000.0 for Q2 2025, which was up 10500.4% from $54000.0 recorded in Q1 2025.
  • In the past 5 years, Aytu Biopharma's Consolidated Net Income ranged from a high of $381000.0 in Q3 2024 and a low of -$53.3 million during Q1 2022
  • Its 5-year average for Consolidated Net Income is -$9.6 million, with a median of -$1.9 million in 2023.
  • In the last 5 years, Aytu Biopharma's Consolidated Net Income tumbled by 54679.52% in 2021 and then skyrocketed by 15888.72% in 2024.
  • Quarter analysis of 5 years shows Aytu Biopharma's Consolidated Net Income stood at -$11.5 million in 2021, then soared by 42.04% to -$6.7 million in 2022, then skyrocketed by 87.46% to -$839000.0 in 2023, then soared by 114.66% to $123000.0 in 2024, then tumbled by 49.59% to $62000.0 in 2025.
  • Its Consolidated Net Income was $62000.0 in Q2 2025, compared to $54000.0 in Q1 2025 and $123000.0 in Q4 2024.